• Founder(s): Prof. Dr. Sven-Erik Behrens, Dr. Hanjo Hennemann & Dr. Martina Behrens
  • Established: July 2017
  • CEO(s): Dr. Hanjo Hennemann
  • Employees: 9
  • Financial Data: €3.1M GO-Bio phase 2 funding in Q2/2018
  • Website:


VEROVACCiNES is fighting infections and widespread use of antibiotics in animal health by using a novel class of combination vaccines. Their aim is to protect animals against infectious diseases. 

Currently, the team at VEROVACCiNES is developing a pipeline of five animal vaccines using a proprietary technology platform to generate yeast-based combination vaccines. Their technology has been validated by demonstrating protection of several target animal species against different viral diseases in proof-of-concept testing.

VEROVACCiNES is based in Halle (Saale), Saxony-Anhalt’s biotech cluster. The location is close to Martin Luther University and biotech companies of various sizes. This provides good access to basic research, trained personnel and helpful networking.